A Phase 2 interventional study of PF-06700841 and Placebo in Chronic Plaque Psoriasis, sponsored by Pfizer. Completed at 44 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-29.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.
Among the 57 studies in Psoriasis by Pfizer, this one is the 15th largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2016, is one of 13 in phase 2, and was the 50th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 212 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 42 interventional studies, 458 across the 15 observational. Of the 56 that completed or were terminated, 46 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Psoriasis by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
Drug: PF-06700841
4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
Drug: PF-06700841
4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
Drug: PF-06700841
4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
Drug: PF-06700841
4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
Drug: PF-06700841
4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
Drug: PF-06700841
4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
Drug: PF-06700841
12 weeks once daily placebo
Other: Placebo
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Baseline (Day 1 pre-dose), Week 12
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12
A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Week 12
Change From Baseline in PASI Scores at Week 4 by Induction Dose
Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Baseline (Day 1 pre-dose), Week 4
Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16
A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Weeks 1, 2, 4, 6, 8, 10, 14, 16
Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16
The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16
Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
Time frame: From first dose of study treatment (Day 1) up to Week 20
Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs
The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).
Time frame: From first dose of study treatment (Day 1) up to Week 20
Change From Baseline in Blood Lipid Level at Weeks 4 and 12
Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.
Time frame: Baseline (Day 1 pre-dose), Weeks 4 and 12
Number of Participants With Any Post-Baseline Laboratory Test Abnormalities
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time \[PT\], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).
Time frame: From first dose of study treatment (Day 1) up to Week 16
Number of Participants With Post-Baseline Vital Sign Abnormalities
Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) \<50 mmHg; 3) sitting pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (\>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP \>=30 mmHg.
Time frame: From first dose of study treatment (Day 1) up to Week 16
Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% change when baseline is \> 200 msec or \>=50% change when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; a change from baseline of 30 to \<60 msec or \>=60 msec.
Time frame: From first dose of study treatment (Day 1) up to Week 16
| Milestone | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 25 | 29 | 26 | 25 | 29 | 25 | 30 | 23 |
| Completed | 21 | 21 | 20 | 20 | 27 | 17 | 22 | 16 |
| Not completed | 4 | 8 | 6 | 5 | 2 | 8 | 8 | 7 |
| Withdrew: Adverse event | 2 | 4 | 1 | 2 | 0 | 1 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 2 | 0 | 1 | 1 | 0 | 1 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 1 | 0 | 4 | 4 | 3 |
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| units on a scale | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -15.85 (-18.31 to -13.39) | -10.56 (-12.96 to -8.16) | -14.28 (-16.75 to -11.81) | -10.14 (-12.62 to -7.66) | -17.28 (-19.55 to -15.02) | -13.27 (-15.78 to -10.76) | -11.88 (-14.16 to -9.59) | -7.21 (-9.96 to -4.46) |
A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| percentage of participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12 | 60.0 (41.68 to 76.44) | 24.1 (11.92 to 40.60) | 57.7 (39.84 to 74.16) | 24.0 (11.01 to 41.95) | 86.2 (71.16 to 95.15) | 24.0 (11.01 to 41.95) | 36.7 (22.11 to 53.31) | 13.0 (3.65 to 30.36) |
Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| units on a scale | PF-06700841 60 mg QD as the Induction Dose | PF-06700841 30 mg QD as the Induction Dose | Placebo as the Induction Dose |
|---|---|---|---|
| Change From Baseline in PASI Scores at Week 4 by Induction Dose | -13.17 (-14.20 to -12.15) | -12.16 (-13.31 to -11.02) | -4.17 (-6.38 to -1.97) |
A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| percentage of participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 0 (0.00 to 11.29) | 6.9 (1.24 to 20.16) | 7.7 (1.38 to 22.29) | 4.0 (0.20 to 17.61) | 0 (0.00 to 9.81) | 4.0 (0.20 to 17.61) | 0 (0.00 to 9.50) | 0 (0.00 to 12.21) |
| Week 2 | 8.0 (1.44 to 23.10) | 13.8 (4.85 to 28.84) | 26.9 (13.38 to 44.68) | 12.0 (3.35 to 28.17) | 3.4 (0.18 to 15.34) | 8.0 (1.44 to 23.10) | 0 (0.00 to 9.50) | 0 (0.00 to 12.21) |
| Week 4 | 24.0 (11.01 to 41.95) | 41.4 (25.89 to 58.25) | 61.5 (43.57 to 77.43) | 36.0 (20.24 to 54.39) | 27.6 (14.53 to 44.29) | 24.0 (11.01 to 41.95) | 36.7 (22.11 to 53.31) | 0 (0.00 to 12.21) |
| Week 6 | 44.0 (26.99 to 62.14) | 41.4 (25.89 to 58.25) | 65.4 (47.38 to 80.60) | 36.0 (20.24 to 54.39) | 51.7 (35.20 to 67.97) | 28.0 (13.95 to 46.22) | 26.7 (14.02 to 42.99) | 8.7 (1.57 to 24.92) |
| Week 8 | 60.0 (41.68 to 76.44) | 37.9 (22.93 to 54.88) | 65.4 (47.38 to 80.60) | 32.0 (17.03 to 50.36) | 65.5 (48.57 to 79.95) | 20.0 (8.23 to 37.54) | 40.0 (24.95 to 56.61) | 8.7 (1.57 to 24.92) |
| Week 10 | 48.0 (30.51 to 65.86) | 24.1 (11.92 to 40.60) | 61.5 (43.57 to 77.43) | 32.0 (17.03 to 50.36) | 72.4 (55.71 to 85.47) | 28.0 (13.95 to 46.22) | 46.7 (30.85 to 63.01) | 13.0 (3.65 to 30.36) |
| Week 14 | 48.0 (30.51 to 65.86) | 17.2 (7.05 to 32.89) | 34.6 (19.40 to 52.62) | 16.0 (5.66 to 32.96) | 75.9 (59.40 to 88.08) | 16.0 (5.66 to 32.96) | 16.7 (6.81 to 31.90) | 8.7 (1.57 to 24.92) |
| Week 16 | 36.0 (20.24 to 54.39) | 10.3 (2.88 to 24.61) | 30.8 (16.33 to 48.70) | 20.0 (8.23 to 37.54) | 58.6 (41.75 to 74.11) | 12.0 (3.35 to 28.17) | 16.7 (6.81 to 31.90) | 8.7 (1.57 to 24.92) |
A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| percentage of participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 12.0 (3.35 to 28.17) | 13.8 (4.85 to 28.84) | 19.2 (7.90 to 36.26) | 20.0 (8.23 to 37.54) | 10.3 (2.88 to 24.61) | 8.0 (1.44 to 23.10) | 3.3 (0.17 to 14.86) | 0 (0.00 to 12.21) |
| Week 2 | 44.0 (26.99 to 62.14) | 37.9 (22.93 to 54.88) | 46.2 (29.21 to 63.79) | 32.0 (17.03 to 50.36) | 41.4 (25.89 to 58.25) | 20.0 (8.23 to 37.54) | 33.3 (19.33 to 49.94) | 0 (0.00 to 12.21) |
| Week 4 | 60.0 (41.68 to 76.44) | 69.0 (52.10 to 82.75) | 69.2 (51.30 to 83.67) | 68.0 (49.64 to 82.97) | 69.0 (52.10 to 82.75) | 60.0 (41.68 to 76.44) | 66.7 (50.06 to 80.67) | 13.0 (3.65 to 30.36) |
| Week 6 | 72.0 (53.78 to 86.05) | 62.1 (45.12 to 77.07) | 73.1 (55.32 to 86.62) | 68.0 (49.64 to 82.97) | 82.8 (67.11 to 92.95) | 60.0 (41.68 to 76.44) | 63.3 (46.69 to 77.89) | 26.1 (12.02 to 45.10) |
| Week 8 | 72.0 (53.78 to 86.05) | 55.2 (38.44 to 71.07) | 73.1 (55.32 to 86.62) | 52.0 (34.14 to 69.49) | 86.2 (71.16 to 95.15) | 56.0 (37.86 to 73.01) | 63.3 (46.69 to 77.89) | 17.4 (6.17 to 35.49) |
| Week 10 | 68.0 (49.64 to 82.97) | 44.8 (28.93 to 61.56) | 73.1 (55.32 to 86.62) | 48.0 (30.51 to 65.86) | 86.2 (71.16 to 95.15) | 48.0 (30.51 to 65.86) | 56.7 (40.16 to 72.13) | 17.4 (6.17 to 35.49) |
| Week 12 | 68.0 (49.64 to 82.97) | 44.8 (28.93 to 61.56) | 69.2 (51.30 to 83.67) | 52.0 (34.14 to 69.49) | 89.7 (75.39 to 97.12) | 48.0 (30.51 to 65.86) | 53.3 (36.99 to 69.15) | 21.7 (8.98 to 40.39) |
| Week 14 | 64.0 (45.61 to 79.76) | 44.8 (28.93 to 61.56) | 61.5 (43.57 to 77.43) | 48.0 (30.51 to 65.86) | 89.7 (75.39 to 97.12) | 36.0 (20.24 to 54.39) | 36.7 (22.11 to 53.31) | 26.1 (12.02 to 45.10) |
| Week 16 | 60.0 (41.68 to 76.44) | 34.5 (20.05 to 51.43) | 53.8 (36.21 to 70.79) | 40.0 (23.56 to 58.32) | 79.3 (63.20 to 90.58) | 40.0 (23.56 to 58.32) | 36.7 (22.11 to 53.31) | 21.7 (8.98 to 40.39) |
A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| percentage of participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 0 (0.00 to 11.29) | 3.4 (0.18 to 15.34) | 0 (0.00 to 10.88) | 0 (0.00 to 11.29) | 0 (0.00 to 9.81) | 0 (0.00 to 11.29) | 0 (0.00 to 9.50) | 0 (0.00 to 12.21) |
| Week 2 | 0 (0.00 to 11.29) | 3.4 (0.18 to 15.34) | 7.7 (1.38 to 22.29) | 0 (0.00 to 11.29) | 0 (0.00 to 9.81) | 0 (0.00 to 11.29) | 0 (0.00 to 9.50) | 0 (0.00 to 12.21) |
| Week 4 | 12.0 (3.35 to 28.17) | 20.7 (9.42 to 36.80) | 42.3 (25.84 to 60.16) | 16.0 (5.66 to 32.96) | 6.9 (1.24 to 20.16) | 8.0 (1.44 to 23.10) | 3.3 (0.17 to 14.86) | 0 (0.00 to 12.21) |
| Week 6 | 16.0 (5.66 to 32.96) | 20.7 (9.42 to 36.80) | 26.9 (13.38 to 44.68) | 12.0 (3.35 to 28.17) | 24.1 (11.92 to 40.60) | 8.0 (1.44 to 23.10) | 20.0 (9.09 to 35.70) | 0 (0.00 to 12.21) |
| Week 8 | 24.0 (11.01 to 41.95) | 17.2 (7.05 to 32.89) | 30.8 (16.33 to 48.70) | 8.0 (1.44 to 23.10) | 34.5 (20.05 to 51.43) | 4.0 (0.20 to 17.61) | 16.7 (6.81 to 31.90) | 0 (0.00 to 12.21) |
| Week 10 | 28.0 (13.95 to 46.22) | 17.2 (7.05 to 32.89) | 26.9 (13.38 to 44.68) | 8.0 (1.44 to 23.10) | 34.5 (20.05 to 51.43) | 8.0 (1.44 to 23.10) | 13.3 (4.69 to 27.96) | 4.3 (0.22 to 19.02) |
| Week 12 | 36.0 (20.24 to 54.39) | 13.8 (4.85 to 28.84) | 26.9 (13.38 to 44.68) | 8.0 (1.44 to 23.10) | 51.7 (35.20 to 67.97) | 8.0 (1.44 to 23.10) | 10.0 (2.78 to 23.86) | 4.3 (0.22 to 19.02) |
| Week 14 | 28.0 (13.95 to 46.22) | 13.8 (4.85 to 28.84) | 11.5 (3.22 to 27.19) | 8.0 (1.44 to 23.10) | 37.9 (22.93 to 54.88) | 4.0 (0.20 to 17.61) | 13.3 (4.69 to 27.96) | 4.3 (0.22 to 19.02) |
| Week 16 | 20.0 (8.23 to 37.54) | 3.4 (0.18 to 15.34) | 15.4 (5.43 to 31.82) | 4.0 (0.20 to 17.61) | 27.6 (14.53 to 44.29) | 8.0 (1.44 to 23.10) | 10.0 (2.78 to 23.86) | 4.3 (0.22 to 19.02) |
The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| units on a scale | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -5.74 (-7.61 to -3.86) | -4.60 (-6.06 to -3.14) | -5.85 (-7.62 to -4.08) | -5.37 (-7.59 to -3.15) | -3.97 (-5.00 to -2.95) | -4.41 (-6.18 to -2.64) | -3.46 (-4.64 to -2.28) | -1.35 (-2.03 to -0.66) |
| Week 2 | -9.44 (-11.74 to -7.15) | -8.35 (-10.07 to -6.63) | -10.79 (-13.05 to -8.52) | -9.49 (-12.40 to -6.58) | -7.86 (-9.38 to -6.35) | -7.79 (-9.79 to -5.79) | -7.93 (-9.64 to -6.22) | -2.28 (-3.21 to -1.36) |
| Week 4 | -12.85 (-15.76 to -9.94) | -12.19 (-14.57 to -9.81) | -14.11 (-16.37 to -11.86) | -13.91 (-16.98 to -10.85) | -11.72 (-13.61 to -9.83) | -12.88 (-15.49 to -10.27) | -13.06 (-15.58 to -10.53) | -4.02 (-6.04 to -2.00) |
| Week 6 | -15.00 (-18.30 to -11.71) | -12.12 (-14.53 to -9.71) | -15.00 (-17.35 to -12.66) | -13.85 (-16.62 to -11.08) | -14.30 (-16.24 to -12.36) | -14.33 (-17.47 to -11.19) | -14.17 (-16.92 to -11.41) | -5.52 (-7.58 to -3.45) |
| Week 8 | -15.94 (-19.40 to -12.49) | -11.09 (-12.90 to -9.27) | -14.97 (-17.66 to -12.27) | -12.87 (-15.69 to -10.04) | -15.82 (-17.81 to -13.84) | -14.27 (-17.51 to -11.03) | -13.83 (-16.79 to -10.87) | -6.56 (-8.61 to -4.51) |
| Week 10 | -16.54 (-20.54 to -12.54) | -9.89 (-12.16 to -7.61) | -15.52 (-18.09 to -12.96) | -11.64 (-14.92 to -8.37) | -16.65 (-18.64 to -14.66) | -14.98 (-18.43 to -11.53) | -12.97 (-16.19 to -9.74) | -6.78 (-9.20 to -4.37) |
| Week 14 | -15.47 (-19.88 to -11.06) | -8.11 (-10.69 to -5.53) | -13.31 (-16.73 to -9.89) | -9.45 (-12.96 to -5.94) | -16.14 (-18.16 to -14.12) | -10.44 (-13.33 to -7.55) | -11.03 (-14.61 to -7.44) | -6.98 (-9.81 to -4.14) |
| Week 16 | -14.16 (-18.68 to -9.64) | -6.59 (-9.09 to -4.09) | -13.00 (-16.60 to -9.40) | -7.83 (-11.56 to -4.11) | -14.38 (-16.74 to -12.01) | -9.62 (-13.08 to -6.16) | -9.13 (-13.94 to -4.33) | -6.76 (-9.80 to -3.72) |
The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
| percent change | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -26.70 (-33.80 to -19.60) | -24.66 (-33.24 to -16.08) | -30.25 (-39.07 to -21.44) | -23.33 (-30.84 to -15.82) | -20.92 (-26.82 to -15.01) | -17.50 (-23.91 to -11.10) | -15.42 (-20.68 to -10.16) | -6.90 (-10.50 to -3.30) |
| Week 2 | -43.66 (-52.81 to -34.52) | -44.17 (-52.75 to -35.59) | -54.27 (-64.17 to -44.36) | -42.58 (-51.17 to -33.98) | -40.89 (-47.94 to -33.83) | -32.46 (-39.75 to -25.16) | -35.89 (-42.69 to -29.09) | -12.81 (-18.29 to -7.33) |
| Week 4 | -57.16 (-67.35 to -46.97) | -63.02 (-72.12 to -53.91) | -72.41 (-82.31 to -62.51) | -64.71 (-72.81 to -56.61) | -60.76 (-68.38 to -53.14) | -53.93 (-62.59 to -45.28) | -58.99 (-67.94 to -50.03) | -25.17 (-34.24 to -16.09) |
| Week 6 | -66.07 (-76.06 to -56.08) | -63.31 (-73.99 to -52.62) | -75.96 (-84.68 to -67.25) | -65.06 (-74.15 to -55.97) | -73.91 (-80.62 to -67.19) | -58.57 (-66.76 to -50.37) | -63.17 (-72.37 to -53.96) | -33.49 (-44.16 to -22.83) |
| Week 8 | -70.11 (-80.95 to -59.27) | -62.25 (-72.42 to -52.07) | -77.05 (-86.69 to -67.41) | -59.88 (-69.78 to -49.97) | -81.04 (-86.69 to -75.40) | -58.32 (-66.39 to -50.25) | -61.38 (-71.80 to -50.96) | -37.76 (-47.73 to -27.80) |
| Week 10 | -70.72 (-83.32 to -58.12) | -57.55 (-69.11 to -46.00) | -78.46 (-85.82 to -71.09) | -53.81 (-64.41 to -43.22) | -84.82 (-89.50 to -80.15) | -61.23 (-69.29 to -53.17) | -57.24 (-68.80 to -45.69) | -39.68 (-50.92 to -28.44) |
| Week 12 | -71.94 (-84.67 to -59.21) | -58.52 (-69.38 to -47.67) | -74.42 (-84.98 to -63.87) | -51.49 (-63.21 to -39.78) | -88.68 (-93.13 to -84.22) | -57.81 (-68.52 to -47.10) | -58.57 (-70.05 to -47.09) | -40.27 (-52.68 to -27.86) |
| Week 14 | -64.15 (-78.24 to -50.05) | -47.87 (-62.17 to -33.56) | -63.20 (-74.36 to -52.05) | -44.30 (-57.51 to -31.09) | -83.39 (-89.74 to -77.04) | -47.84 (-60.18 to -35.49) | -47.52 (-59.86 to -35.18) | -39.48 (-52.09 to -26.88) |
| Week 16 | -57.28 (-72.02 to -42.54) | -38.48 (-51.85 to -25.10) | -60.56 (-72.71 to -48.42) | -36.63 (-51.43 to -21.83) | -74.18 (-83.22 to -65.15) | -44.58 (-58.96 to -30.19) | -42.29 (-59.96 to -24.63) | -38.79 (-51.92 to -25.66) |
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
| Participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Treatment-emergent AEs | 19 | 21 | 18 | 18 | 21 | 16 | 23 | 13 |
| Treatment-emergent SAEs | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).
| Participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs | 2 | 4 | 1 | 2 | 0 | 2 | 2 | 0 |
Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.
| milligram per deciliter (mg/dL) | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| LDL Cholesterol, Week 4 | 15.91 (7.95 to 23.86) | 11.27 (4.31 to 18.23) | 15.00 (-0.63 to 30.63) | 15.88 (6.63 to 25.12) | 8.96 (0.99 to 16.92) | -2.21 (-11.04 to 6.63) | 7.60 (-4.39 to 19.59) | -6.28 (-10.56 to -2.00) |
| LDL Cholesterol, Week 12 | 8.71 (1.04 to 16.39) | 6.00 (-4.73 to 16.73) | -0.74 (-11.67 to 10.20) | 6.85 (-2.06 to 15.76) | 14.10 (6.63 to 21.57) | -5.33 (-18.24 to 7.57) | 3.95 (-7.79 to 15.70) | -4.00 (-9.71 to 1.71) |
| HDL Cholesterol, Week 4 | 12.09 (8.07 to 16.11) | 9.14 (5.84 to 12.45) | 10.92 (7.38 to 14.46) | 8.58 (5.84 to 11.33) | 6.36 (3.91 to 8.80) | 6.76 (2.93 to 10.59) | 9.39 (7.03 to 11.75) | 0.00 (-5.14 to 5.14) |
| HDL Cholesterol, Week 12 | 5.00 (1.29 to 8.71) | 5.48 (1.66 to 9.29) | 2.48 (-0.31 to 5.26) | -0.24 (-2.55 to 2.08) | 4.74 (1.30 to 8.18) | 4.37 (1.04 to 7.70) | 2.88 (-0.24 to 5.99) | -2.73 (-6.32 to 0.85) |
| Total Cholesterol, Week 4 | 34.39 (24.01 to 44.77) | 29.46 (18.68 to 40.25) | 31.32 (15.20 to 47.44) | 26.33 (15.85 to 36.82) | 15.14 (-0.16 to 30.45) | 10.36 (-1.70 to 22.42) | 14.00 (0.14 to 27.86) | -4.42 (-10.90 to 2.06) |
| Total Cholesterol, Week 12 | 19.50 (9.95 to 29.05) | 15.67 (2.74 to 28.59) | -1.86 (-13.78 to 10.07) | 7.05 (-3.25 to 17.35) | 20.37 (3.06 to 37.68) | 0.68 (-14.51 to 15.87) | 4.33 (-8.86 to 17.53) | -6.40 (-13.68 to 0.88) |
| Triglycerides, Week 4 | 34.74 (-8.43 to 77.91) | 29.68 (10.42 to 48.94) | 8.04 (-20.07 to 36.15) | 8.92 (-21.83 to 39.66) | -65.11 (-204.94 to 74.72) | 19.60 (-3.04 to 42.24) | -59.75 (-157.79 to 38.29) | 15.26 (-11.07 to 41.60) |
| Triglycerides, Week 12 | 27.86 (-4.68 to 60.41) | 48.33 (-32.67 to 129.34) | -85.00 (-213.81 to 43.81) | 2.67 (-27.36 to 32.70) | -18.96 (-198.51 to 160.59) | 6.32 (-19.21 to 31.84) | -67.79 (-185.53 to 49.95) | 1.87 (-24.28 to 28.01) |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time \[PT\], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).
| Participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Any Post-Baseline Laboratory Test Abnormalities | 17 | 20 | 20 | 16 | 21 | 20 | 18 | 11 |
Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) \<50 mmHg; 3) sitting pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (\>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP \>=30 mmHg.
| Participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Sitting DBP <50 mm Hg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting DBP increase >=20 mm Hg | 1 | 1 | 3 | 2 | 0 | 0 | 0 | 0 |
| Sitting DBP decrease >=20 mm Hg | 3 | 0 | 2 | 2 | 1 | 2 | 2 | 1 |
| Sitting SBP <90 mm Hg | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting SBP increase >=30 mm Hg | 1 | 3 | 2 | 1 | 0 | 1 | 0 | 0 |
| Sitting SBP decrease >=30 mm Hg | 2 | 2 | 1 | 2 | 1 | 3 | 2 | 1 |
| Sitting pulse rate <40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting pulse rate >120 bpm | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% change when baseline is \> 200 msec or \>=50% change when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; a change from baseline of 30 to \<60 msec or \>=60 msec.
| Participants | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| PR interval >=300 msec | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| %Change in PR interval >=25/50% | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| QRS duration >=140 msec | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| %Change in QRS duration >=50% | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| QT interval >=500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTc >=450 to <480 msec | 6 | 1 | 2 | 0 | 1 | 1 | 0 | 1 |
| QTc >=480 to <500 msec | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| QTc >=500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTc change >=30 to <60 msec | 2 | 0 | 2 | 1 | 3 | 3 | 0 | 1 |
| QTc change >=60 msec | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 |
Collected over From first dose of study treatment up to 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | 1/25 (4%) | 2/25 (8%) | 11/25 (44%) |
| PF-06700841 60 mg QD Followed by 10 mg QD | 0/29 (0%) | 1/29 (3.4%) | 14/29 (48.3%) |
| PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | 0/26 (0%) | 1/26 (3.8%) | 13/26 (50%) |
| PF-06700841 60 mg QD Followed by Placebo | 0/25 (0%) | 1/25 (4%) | 13/25 (52%) |
| PF-06700841 30 mg QD | 0/29 (0%) | 0/29 (0%) | 13/29 (44.8%) |
| PF-06700841 30 mg QD Followed by 10 mg QD | 0/25 (0%) | 0/25 (0%) | 12/25 (48%) |
| PF-06700841 30 mg QD Followed by 100 mg QW | 0/30 (0%) | 0/30 (0%) | 16/30 (53.3%) |
| Placebo | 0/23 (0%) | 0/23 (0%) | 9/23 (39.1%) |
| Event | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| Angina pectorisCardiac disorders | 1/25 | 0/29 | 0/26 | 0/25 | 0/29 | 0/25 | 0/30 | 0/23 |
| Chest painGeneral disorders | 0/25 | 0/29 | 0/26 | 1/25 | 0/29 | 0/25 | 0/30 | 0/23 |
| Gun shot woundInjury, poisoning and procedural complications | 1/25 | 0/29 | 0/26 | 0/25 | 0/29 | 0/25 | 0/30 | 0/23 |
| PneumoniaInfections and infestations | 0/25 | 0/29 | 1/26 | 0/25 | 0/29 | 0/25 | 0/30 | 0/23 |
| SepsisInfections and infestations | 0/25 | 0/29 | 1/26 | 0/25 | 0/29 | 0/25 | 0/30 | 0/23 |
| AnaemiaBlood and lymphatic system disorders | 0/25 | 1/29 | 0/26 | 0/25 | 0/29 | 0/25 | 0/30 | 0/23 |
| Event | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/25 | 3/29 | 3/26 | 3/25 | 5/29 | 6/25 | 4/30 | 3/23 |
| Upper respiratory tract infectionInfections and infestations | 2/25 | 1/29 | 5/26 | 1/25 | 2/29 | 0/25 | 3/30 | 1/23 |
| HeadacheNervous system disorders | 1/25 | 2/29 | 3/26 | 3/25 | 4/29 | 1/25 | 0/30 | 1/23 |
| PruritusSkin and subcutaneous tissue disorders | 0/25 | 0/29 | 1/26 | 3/25 | 1/29 | 0/25 | 1/30 | 0/23 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/25 | 1/29 | 3/26 | 1/25 | 0/29 | 2/25 | 0/30 | 0/23 |
| DiarrhoeaGastrointestinal disorders | 0/25 | 1/29 | 0/26 | 1/25 | 0/29 | 1/25 | 3/30 | 1/23 |
| NauseaGastrointestinal disorders | 1/25 | 1/29 | 1/26 | 2/25 | 0/29 | 0/25 | 1/30 | 2/23 |
| Back painMusculoskeletal and connective tissue disorders | 1/25 | 2/29 | 0/26 | 0/25 | 2/29 | 2/25 | 1/30 | 2/23 |
| FatigueGeneral disorders | 1/25 | 1/29 | 1/26 | 2/25 | 0/29 | 1/25 | 0/30 | 1/23 |
| VomitingGastrointestinal disorders | 0/25 | 1/29 | 1/26 | 1/25 | 0/29 | 2/25 | 0/30 | 0/23 |
All participants who received at least 1 dose of PF-06700841 or placebo.
| Age, Continuous(years) | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 49.0 ± 14.69 | 44.6 ± 13.71 | 45.5 ± 12.93 | 48.4 ± 15.47 | 44.2 ± 10.92 | 44.0 ± 11.56 | 43.2 ± 12.28 | 50.3 ± 12.23 | 46.0 ± 13.04 |
| Age, Customized(Participants) | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| 18-44 Years | 8 | 14 | 10 | 8 | 14 | 12 | 14 | 8 | 88 |
| 45-64 Years | 14 | 13 | 14 | 13 | 14 | 13 | 16 | 12 | 109 |
| >=65 Years | 3 | 2 | 2 | 4 | 1 | 0 | 0 | 3 | 15 |
| Sex: Female, Male(Participants) | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 9 | 8 | 14 | 4 | 10 | 8 | 7 | 4 | 64 |
| Male | 16 | 21 | 12 | 21 | 19 | 17 | 23 | 19 | 148 |
| Ethnicity (NIH/OMB)(Participants) | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 4 | 2 | 6 | 5 | 4 | 4 | 33 |
| Not Hispanic or Latino | 21 | 25 | 22 | 23 | 23 | 20 | 26 | 19 | 179 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD | PF-06700841 60 mg QD Followed by 10 mg QD | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) | PF-06700841 60 mg QD Followed by Placebo | PF-06700841 30 mg QD | PF-06700841 30 mg QD Followed by 10 mg QD | PF-06700841 30 mg QD Followed by 100 mg QW | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 22 | 27 | 23 | 24 | 27 | 22 | 25 | 19 | 189 |
| Black or African American | 3 | 0 | 3 | 0 | 1 | 1 | 1 | 2 | 11 |
| Asian | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 4 |
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| Other | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2016 to primary completion in Mar 2018, 15 months.
Results were first posted in Mar 2019, 1 year after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 15 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06700841